Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VBIV

VBI Vaccines (VBIV) Stock Price, News & Analysis

VBI Vaccines logo

About VBI Vaccines Stock (NASDAQ:VBIV)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$0.02
$0.79
52-Week Range
N/A
Volume
29.90 million shs
Average Volume
3.66 million shs
Market Capitalization
$1.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

Remove Ads
Receive VBIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.

VBIV Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Why Is VBI Vaccines (VBIV) Stock Up 62% Today?
See More Headlines

VBIV Stock Analysis - Frequently Asked Questions

VBI Vaccines Inc. (NASDAQ:VBIV) announced its earnings results on Monday, March, 13th. The biopharmaceutical company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.40) by $0.20. The biopharmaceutical company had revenue of $0.29 million for the quarter, compared to analysts' expectations of $1.98 million. VBI Vaccines had a negative net margin of 881.79% and a negative trailing twelve-month return on equity of 525.42%.

Shares of VBI Vaccines reverse split before market open on Wednesday, April 12th 2023. The 1-20 reverse split was announced on Wednesday, April 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that VBI Vaccines investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Pfizer (PFE) and Novavax (NVAX).

Company Calendar

Last Earnings
3/13/2023
Today
4/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VBIV
Fax
N/A
Employees
22
Year Founded
2001

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-92,840,000.00
Net Margins
-881.79%
Pretax Margin
-881.79%

Debt

Sales & Book Value

Annual Sales
$9.41 million
Price / Cash Flow
N/A
Book Value
$0.32 per share
Price / Book
N/A

Miscellaneous

Free Float
25,713,000
Market Cap
$1.87 million
Optionable
Optionable
Beta
2.18

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:VBIV) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners